An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

Liu, Joyce F.; Burris, Howard A.; Wang, Judy S.; Barroilhet, Lisa; Gutierrez, Martin; Wang, Yulei; Vaze, Anjali; Commerford, Renee; Royer-Joo, Stephanie; Choeurng, Voleak; Humke, Eric W.; Moore, Kathleen N.

doi:10.1016/j.ygyno.2021.09.023

Cited by 27 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genentech Inc., also devotes itself to studying the mechanisms, pharmacokinetics, and structures of ADCs and to developing novel ADC agents. The phase I dose-escalation study of DMUC4064A, an innovative ADC drug that targets MUC16 expressed in the ovarian cancer cell, was completed in 2021 ( Liu et al, 2021 ). Mem Sloan Kettering Canc Ctr released the results of its first ADC clinical trial in 2008, the phase I trial of MLN2704, a prostate-specific membrane antigen-targeted immunoconjugate, in the treatment of prostate cancer ( Galsky et al, 2008 ).…”

Section: Discussionmentioning

confidence: 99%

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce.Methods: Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and R package Bibliometrix.Results: A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the Journal of Clinical Oncology. A total of 37 burst references and five burst references were identified between 2017–2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns.Conclusion: This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns.

show abstract

Section: Discussionmentioning

confidence: 99%

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Other ADCs have been developed and are under preclinical and clinical evaluation in ovarian cancer. These ADCs have been directed against specific antigens expressed in several solid tumors including ovarian cancer, among which the most investigated are cancer antigen 125 (CA125 or MUC16) [57,67,68], NaPi2b [58,59,[69][70][71], Trop2 [72], TF [73][74][75], protein tyrosine kinase 7 (PTK7) [76], CD166 and Notch3 [77].…”

Section: Other Adcs In Ovarian Cancermentioning

confidence: 99%

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

Nerone

Grande

Sessa

et al. 2022

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicity of classic chemotherapy agents. These drugs have been extensively studied both in solid and hematologic malignancies, leading to substantial improvement in the therapeutic landscape for several tumors. Despite no ADC have been yet approved for the treatment of gynecological malignancies, some agents have shown promising results and might have the potential to become part of the standard of care. Among them, mirvetuximab soravtansine has shown activity in platinum-resistant ovarian cancer with high folate-α receptor expression, as a single agent and in combination. Tisotumab vedotin is active in patients with pre-treated cervical cancer, and further investigation is ongoing. The purpose of this review is to summarize the structural and functional characteristics of ADCs and analyze the most recent and promising data regarding the clinical development of ADCs in gynecological malignancies. The available data on the efficacy of the more studied ADCs in ovarian, endometrial, and cervical cancers will be discussed along with toxicities of special interest, the mechanisms of resistance, and future possible drugs combination.

show abstract

“…There were also 19 SDs (35%) and 12 PDs (22%). The best responses were SD ( n = 4, 57%) and PD ( n = 3, 43%) in seven patients with MUC16 IHC scores of 0 or 1+ ( Liu et al, 2021 ). However, clinical development of DMUC4064A has been discontinued for non-safety-related reasons.…”

Section: Use Of Adcs In Gynecologic Cancermentioning

confidence: 99%

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint inhibitors have made significant progress in the treatment of various cancers. However, due to the low ICI responsive rate for the gynecologic cancer, ICI two-drug combination therapy tends to be a predominant way for clinical treatment. Antibody-drug conjugates, a promising therapeutic modality for cancer, have been approved by the FDA for breast cancer, lymphoma, multiple myeloma and gastric cancer. On September 2021, the FDA granted accelerated approval to tisotumab vedotin for patients with recurrent or metastatic cervical cancer. Currently, the role of therapy of ADCs on gynecologic tumors was also included in medication regimens. Now more than 30 ADCs targeting for 20 biomarkers are under clinical trials in the field, including monotherapy or combination with others for multiple lines of therapy. Some ADCs have been proved to enhance the antitumor immunity effect on both pre-clinical models and clinical trials. Therefore, combination of ADCs and ICIs are expected in clinical trials. In this review, we discuss current development of ADCs in gynecologic oncology and the combination effects of ICIs and ADCs.

show abstract

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

Cited by 27 publications

References 22 publications

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

Contact Info

Product

Resources

About